The tide of deaths due to unintentional prescription opioid toxicity must be stemmed.
Adherence to drug therapy in hepatitis C increased total costs in year 1 relative to nonadherent patients, then decreased total costs in year 2.
A controlled trial of a system for rectifying and preventing drug-related problems was conducted to evaluate improvement in the efficiency of resource utilization.
Medicare Part D plans can change their cost-sharing structure and formularies every year. As such, beneficiaries should annually reevaluate plan offerings to minimize their out-of-pocket costs.
Due to constantly changing business models, various product configurations and distribution channels, there is no established standard to ensure that a product administered to a patient is not compromised.Â
Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, discuss emerging agents in the pipeline and the future treatment landscape for CLL.
Negative findings were reported for both clinical and imaging measures in a Phase II randomized trial of riluzole in comparison to placebo in patients with very early multiple sclerosis (MS).
A case involving a 69-year-old man who is admitted to the burn center for management following a 31% full thickness burn and begins to lose significant lean body mass.
A new drug was recently given tentative approval by the FDA to help patients with both type 1 and type 2 diabetes.
Medication adherence is defined as the act of patients taking their medications as prescribed by their health care provider.
South African child with HIV reaches 8-plus year survival after only 40 weeks of antiretroviral therapy in infancy.
An examination of payer coverage for multiple sclerosis drugs shows variation in how these drugs are covered and in the evidence that payers review to make these decisions.
Peer-reviewed research conducted by the National Pharmaceutical Council (NPC) and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center over the past 2 years sheds some light on what’s behind discrepancies in coverage decisions from one insurer to the next.
Cancer patient Beth Wallace provides advice to patients with leiomyosarcoma, as well as to women with cancer in general.
So, the initial meet and greet at Mid-Year went well. You have selected the 'perfect' program. Now, it is time to declare that intention in writing.
Current treatment guidelines utilized by healthcare provider organizations and managed care organization insurance coverage policies for growth hormone therapy are reviewed.
Biosimilars for rituximab, trastuzumab, and bevacizumab are currently approved for use in the European Union.
Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.
Ms. Christopher is a freelance writer based in Portland, Ore.
How can you engage patients to adapt healthy behaviors and be adherent? Motivational Interviewing may be the missing piece.
The placement of clinical pharmacists at the nexus of functional pharmacogenomics and in specialty pharmacy care makes good sense.